Nicholas P. Restifo

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Schelker RC, Fioravanti J, Mastrogiovanni F, et al. (2024) LIM-domain-only 4 (LMO4) enhances CD8 T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling. Signal Transduction and Targeted Therapy. 9: 199
Restifo NP, Gattinoni L. (2024) Synthetic soldiers: Turning T cells into immortal warriors. The Journal of Experimental Medicine. 221
Islam SMR, Maeda T, Tamaoki N, et al. (2023) Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells. Cancer Research Communications. 3: 917-932
Palmer DC, Webber BR, Patel Y, et al. (2022) Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. Med (New York, N.Y.)
Kishton RJ, Patel SJ, Decker AE, et al. (2022) Cancer genes disfavoring T cell immunity identified via integrated systems approach. Cell Reports. 40: 111153
Kishton RJ, Vodnala SK, Vizcardo R, et al. (2021) Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity. Current Opinion in Immunology. 74: 39-45
Mo F, Yu Z, Li P, et al. (2021) An engineered IL-2 partial agonist promotes CD8 T cell stemness. Nature
Hippen KL, Furlan SN, Roychoudhuri R, et al. (2021) Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. Cytotherapy
Xu N, Palmer DC, Robeson AC, et al. (2021) STING agonist promotes CAR T cell trafficking and persistence in breast cancer. The Journal of Experimental Medicine. 218
Dersh D, Phelan JD, Gumina ME, et al. (2020) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity